BrainStorm (OTC.OB:BCLI) is a biotechnology company developing innovative adult stem cell therapies for highly debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD).  Our proprietary process for the propagation and differentiation of autologous, Mesenchymal Stem Cells (MSC) into NeuroTrophic Factor (NTF)-secreting cells, and their transplantation at or near the site of damage, offers the hope of repairing degenerated tissues and curing the underlying pathology, rather than simply treating its symptoms... read more
BrainStorm's management and scientific team are passionately devoted to the Company's mission: regenerating the mind... in their lifetime.